Calcium is a critical cation involved in cellular transport, membrane function, and bone metabolism. Hypercalcaemia, or calcium in systemic excess, is harmful to the function of excitable membranes leading to skeletal muscle and gastrointestinal smooth muscle fatigue. Effects on cardiac muscle include a shortened QT interval and increased risk of cardiac arrest at very high calcium levels. Neurological sequelae include depression, irritability, and, with high enough levels, coma. Hypercalcaemia quickly exceeds renal capacity for calcium re-absorption, and calcium spills into urine, complexing with phosphate, leading to nephrolithiasis. High calcium may lead to precipitation in soft tissues such as the kidney where renal function may be severely damaged. Hypercalcaemia also causes dehydration by inducing renal resistance to vasopressin, leading to nephrogenic diabetes insipidus. Dehydration, in turn, leads to further increase in serum calcium concentration.
Hypercalcaemia is diagnosed when the concentration of serum calcium is two standard deviations above the mean value found in people with normal calcium levels, in at least two samples taken at least 1 week apart. Normal serum or plasma total calcium should be 2.13 to 2.63 mmol/L (8.5 to 10.5 mg/dL) and ionised calcium should be 1.15 to 1.27 mmol/L (4.6 to 5.1 mg/dL).
Only about 1% of the total body calcium is in the extracellular fluid, the rest being in bone and intracellular compartments. About half the circulating calcium is bound to proteins, primarily albumin, while the remainder is ionised and constitutes the physiologically pertinent fraction.
Calcium levels are strictly controlled by parathyroid hormone (PTH), released from the parathyroid glands when the ionised calcium is perceived as low. PTH raises calcium by enhancement of vitamin D metabolism in the kidney, stimulating bone resorption, and increasing phosphate excretion in the kidney. When calcium is perceived as high, the parathyroid glands stop releasing PTH. Thyrocalcitonin from the 'c' cells of the thyroid can lower calcium levels, but its role in calcium balance is minor.
Calcium is absorbed at about 10% efficiency and the absorption relies upon vitamin D. Vitamin D₃ is synthesised in the skin by the reaction of its cholesterol antecedents with ultraviolet B light (290-320 nm); the reaction is triggered when sunlight strikes exposed skin. Dietary sources are usually negligible, except among Arctic peoples who consume a large amount of vitamin D₃ from oily fish and mammals. Vitamin D₃ is converted to the 25-hydroxy metabolite by hepatic pathways and a second hydroxylation to calcitriol or 1,25-dihydroxy vitamin D₃ occurs in renal parenchyma. 1,25-dihydroxy vitamin D₃ increases intestinal calcium absorption. Phosphate solubility is closely related to calcium balance. Any factor causing a rise in phosphate, such as renal failure, will lead to a fall in ionised calcium.
Symptoms and signs
Hypercalcaemia may be mild and occur without symptoms. History may also identify symptoms of high calcium such as renal stones typical of hyperparathyroidism or lethargy, easy fatigue, confusion, depression, irritability, constipation, and polyuria and polydipsia. Chronic symptoms are more consistent with hyperparathyroidism, whereas more recent onset of symptoms suggests malignancy.
Elevated calcium may require an intervention to prevent complications such as osteoporosis. Severe hypercalcaemia is a life-threatening electrolyte emergency requiring prompt recognition and urgent treatment.
Patients with asymptomatic primary hyperparathyroidism (mild hypercalcaemia, generally within 1 mg/dL of the upper limit of the normal range), may undergo parathyroid surgery in the absence of medical contraindications. Surgery is not, however, mandatory in all patients with asymptomatic disease; recommendations for monitoring those who do not undergo parathyroid surgery should be followed.
Rajeev Parameswaran, MD
Consultant Endocrine and General Surgeon
National University Cancer Institute, Singapore
RP declares that he has no competing interests.
Hrishikesh Salgaonkar, MD
Endocrine and Minimally invasive Surgery
National University Hospital
HS declares that he has no competing interests.
Dr Rajeev Parameswaran and Dr Hirshikesh Salgaonkar would like to gratefully acknowledge Dr Ronald Merrell, the previous contributor to this topic. RM declares that he has no competing interests.
Udaya Kabadi, MD, FRCP(C), FACP, FACE
Department of Internal Medicine
VA Medical Center
University of Iowa
UK declares that he has no competing interests.
Wail Malaty, MD
Department of Family Medicine
University of North Carolina
Assistant Program Director
MAHEC Rural Family Medicine Residency
WM declares that he has no competing interests.
Richard Quinton, MD
Consultant and Senior Lecturer
Newcastle University and Royal Victoria Infirmary
RQ has been reimbursed by Amgen, the manufacturer of Cinacalcet, for attending a conference and for giving an educational seminar (total under £1,200 over past 3 years).
Use of this content is subject to our disclaimer